Minireviews
Copyright ©The Author(s) 2022.
World J Hepatol. Sep 27, 2022; 14(9): 1704-1717
Published online Sep 27, 2022. doi: 10.4254/wjh.v14.i9.1704
Table 1 illustrates the non-alcoholic fatty liver disease activity scoring system
Group
Definition
Scoring
Steatosis< 5%0
5%-33%1
> 33%-66%2
> 66%3
Lobular inflammationNo foci0
< 2 foci per 200× field1
2-4 foci per 200× field2
> 4 foci per 200× field3
Hepatocyte ballooningNone0
Few 1
Many2
FibrosisNo fibrosis0
Zone 3 mild perisinusoidal fibrosis1a
Zone 3 moderate perisinusoidal fibrosis1b
Periportal/portal fibrosis only1c
Zone 3+ periportal/portal fibrosis2
Bridging fibrosis3
Cirrhosis4
Table 2 Characteristics of patients who underwent intra-gastric balloons insertion
Variable
2014-2016, n (%)
2017-2018, n (%)
Total IGBs17267
Total number of patients12760
Age (yr) (mean; min-max)46.8 (11.9;19-73)46.6 (11.7;21-67)
Sex
Male56 (27)17 (25)
Female126 (73)50 (75)
Baseline weight (kg) (mean; min-max)110.0 (19.5;67-173.3)114.6 (21.6;70-165)
Balloon number
1102 (59)41 (61)
246 (27)14 (20)
319 (11)5 (7)
45 (3)3 (4)
5-2 (3)
6-2 (3)
Table 3 Comparison weight loss
Variable
2014-2016
2017-2018
Baseline weight (kg) (mean)110.0 (19.5)114.6 (21.6)
Weight at removal (kg) (mean) 101 (19.8)103.5 (21.2)
Weight loss (kg) (mean)8.9 (8.6)10.2 (6.8)
Weight loss as %BW (%) (mean)7.9 (7.5)9.1 (6.1)